Figure 6
From: Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer
SW IV-134 is a potent single-agent cancer drug in a peritoneal mouse xenograft model of ovarian cancer. (A) Female SCID mice were inoculated intraperitoneally with 5 × 106 SKOV3-Luc cells. Treatment was initiated with intraperitoneal injections of SW43, SW IV-134, or vehicle control 7 days after tumor cell inoculation, and continued for a total of 3 weeks. Mice were imaged once a week during the treatment period. Change in bioluminescence photon flux during treatment in each experimental arm (n = 15) was evaluated. Bioluminescent signals at each time point were averaged per treatment group (mean ± SEM). Significant differences were noted between vehicle vs. SW IV-134 and SW43 vs. SW IV-134 (p < 0.0097, one-way ANOVA). (B) Bioluminescent images at the end of the treatment (day 21) of one representative mouse per treatment arm (n = 15). Image intensity is displayed as radiance (photons/s/cm2/sr). (C) Kaplan-Meier survival analysis. At the end of the 3 week treatment, 5 mice from each experimental group were subjected to necropsy. The remaining 10 mice from each treatment group were followed until death to examine overall survival (p < 0.0108, Log-rank test).